

NCT ID	NCT03400332
Title	A Study of BMS-986253 in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Advanced Cancers
Phase	Phase 2
Date Added	2018-01-17
Location	Arkansas, United States California, United States Colorado, United States Georgia, United States Maryland, United States Massachusetts, United States Michigan, United States Nebraska, United States Nevada, United States New Jersey, United States New York, United States Oklahoma, United States Oregon, United States Pennsylvania, United States South Carolina, United States Texas, United States Utah, United States Virginia, United States Australia Belgium Canada France Germany Italy Poland Spain Sweden Switzerland United Kingdom
Prior IO Allowed	No
CRC-directed	No
Status	Active, not recruiting
Drugs	BMS-986253, Ipilimumab, Nivolumab
Tags	MSI-H/ MMRd, MSS/ MMRp

NCT ID	NCT06322693
Title	A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)
Phase	Phase 1
Date Added	2024-03-21

Location	Arizona, United States California, United States Colorado, United States Connecticut, United States District of Columbia, United States Florida, United States Georgia, United States Illinois, United States Iowa, United States Kansas, United States Kentucky, United States Maryland, United States Massachusetts, United States Michigan, United States Minnesota, United States New Jersey, United States New York, United States Ohio, United States Oregon, United States Pennsylvania, United States South Carolina, United States Tennessee, United States Texas, United States Virginia, United States Washington, United States Wisconsin, United States Korea, Republic of Spain
Prior IO Allowed	No
CRC-directed	Yes
Status	Recruiting
Drugs	Carboplatin, cisplatin, Docetaxel, Nivolumab, Pemetrexed, TSR-022, TSR-033, TSR-042
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT03217747
Title	Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced Malignancies
Phase	Phase 1, Phase 2
Date Added	2017-07-14
Location	Texas, United States
Prior IO Allowed	No
CRC-directed	No
Status	Active, not recruiting
Drugs	Anti-OX40 Antibody PF-04518600, Avelumab, Utomilumab, Bavencio
Tags	MSS/ MMRp
NCT ID	NCT05141721
Title	A Study of a Personalized Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer
Phase	Phase 2
Date Added	2021-12-02

Location	Arizona, United States Arkansas, United States California, United States Colorado, United States Connecticut, United States Florida, United States Illinois, United States Indiana, United States Kansas, United States Kentucky, United States Maryland, United States Michigan, United States Nevada, United States New Jersey, United States New York, United States Ohio, United States Oregon, United States Pennsylvania, United States South Carolina, United States Tennessee, United States Texas, United States Utah, United States Virginia, United States Wisconsin, United States
Prior IO Allowed	No
CRC-directed	Yes
Status	Active, not recruiting
Drugs	Atezolizumab, Bevacizumab, Fluoropyrimidine, GRT-C901, GRT-R902, Ipilimumab, oxaliplatin
Tags	MSS/ MMRp
NCT ID	NCT04104776
Title	A Study of CPI-0209 in Patients With Advanced Solid Tumors and Lymphomas
Phase	Phase 1
Date Added	2019-09-26
Location	Georgia, United States Illinois, United States Maryland, United States Massachusetts, United States Michigan, United States New Jersey, United States New York, United States Ohio, United States Texas, United States Virginia, United States Washington, United States France Italy Korea, Republic of Poland Spain United Kingdom
Prior IO Allowed	No
CRC-directed	No
Status	Recruiting
Drugs	CPI-0209, CPI-0209
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT05019534
Title	Tolerability and Safety of Vemurafenib, Cetuximab Combined With Camrelizumab for BRAF V600E-mutated /MSS Metastatic Colorectal Cancer
Phase	Phase 1

Date Added	2021-08-25
Location	China
Prior IO Allowed	No
CRC-directed	Yes
Status	Recruiting
Drugs	Camrelizumab, Cetuximab Injection [Erbix], Vemurafenib Oral Tablet [Zelboraf]
Tags	MSS/ MMRp
NCT ID	NCT03981146
Title	A Phase II Trial Assessing Nivolumab in Class II Expressing Microsatellite Stable Colorectal Cancer
Phase	Phase 2
Date Added	2019-06-10
Location	United Kingdom
Prior IO Allowed	No
CRC-directed	Yes
Status	Active, not recruiting
Drugs	Nivolumab, Opdivo
Tags	MSS/ MMRp
NCT ID	NCT04973163
Title	A Study to Test Different Doses of BI 1823911 Alone and Combined With Other Medicines in People With Different Types of Advanced Cancer With KRAS Mutation
Phase	Phase 1
Date Added	2021-07-22
Location	Texas, United States Belgium Spain United Kingdom
Prior IO Allowed	No
CRC-directed	No
Status	Active, not recruiting
Drugs	BI 1701963, BI 1823911, Midazolam
Tags	MSS/ MMRp
NCT ID	NCT03313778
Title	Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Participants With Resected Solid Tumors and in Combination With Pembrolizumab in Participants With Unresectable Solid Tumors
Phase	Phase 1
Date Added	2017-10-18
Location	Arizona, United States California, United States District of Columbia, United States Florida, United States Massachusetts, United States New Jersey, United States New York, United States North Carolina, United States Ohio, United States Oregon, United States Pennsylvania, United States Tennessee, United States Australia Japan United Kingdom
Prior IO Allowed	No

CRC-directed	No
Status	Recruiting
Drugs	mRNA-4157, Pembrolizumab, Keytruda
Tags	MSS/ MMRp
<hr/>	
NCT ID	NCT05308446
Title	Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF Mutation
Phase	Phase 2
Date Added	2022-04-04
Location	Arizona, United States California, United States Colorado, United States Georgia, United States Hawaii, United States Idaho, United States Illinois, United States Indiana, United States Iowa, United States Louisiana, United States Michigan, United States Minnesota, United States Missouri, United States Montana, United States New Hampshire, United States New Jersey, United States New York, United States North Carolina, United States Ohio, United States Oklahoma, United States Oregon, United States Pennsylvania, United States Rhode Island, United States South Carolina, United States Tennessee, United States Texas, United States Utah, United States Vermont, United States Washington, United States West Virginia, United States Wisconsin, United States Puerto Rico
Prior IO Allowed	No
CRC-directed	Yes
Status	Active, not recruiting
Drugs	cetuximab, encorafenib, Nivolumab, Braftovi, Erbitux, Opdivo
Tags	MSS/ MMRp